172 related articles for article (PubMed ID: 34026925)
1. Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.
Matossian MD; Hoang VT; Burks HE; La J; Elliott S; Brock C; Rusch DB; Buechlein A; Nephew KP; Bhatt A; Cavanaugh JE; Flaherty PT; Collins-Burow BM; Burow ME
Oncoscience; 2021; 8():64-71. PubMed ID: 34026925
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
5. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer.
Bhatt AB; Wright TD; Barnes V; Chakrabarty S; Matossian MD; Lexner E; Ucar DA; Miele L; Flaherty PT; Burow ME; Cavanaugh JE
Transl Oncol; 2021 Jun; 14(6):101046. PubMed ID: 33761370
[TBL] [Abstract][Full Text] [Related]
6. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
Liu F; Zhang H; Song H
Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304
[TBL] [Abstract][Full Text] [Related]
8. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
9. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
10. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract][Full Text] [Related]
11. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.
Simões AE; Pereira DM; Gomes SE; Brito H; Carvalho T; French A; Castro RE; Steer CJ; Thibodeau SN; Rodrigues CM; Borralho PM
Cell Death Dis; 2015 Apr; 6(4):e1718. PubMed ID: 25855966
[TBL] [Abstract][Full Text] [Related]
12. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
Pavan S; Meyer-Schaller N; Diepenbruck M; Kalathur RKR; Saxena M; Christofori G
Oncogene; 2018 Aug; 37(31):4197-4213. PubMed ID: 29713055
[TBL] [Abstract][Full Text] [Related]
13. Stat3 upregulates MEK5 expression in human breast cancer cells.
Song H; Jin X; Lin J
Oncogene; 2004 Oct; 23(50):8301-9. PubMed ID: 15378007
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
[TBL] [Abstract][Full Text] [Related]
15. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
16. MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments.
Miranda M; Rozali E; Khanna KK; Al-Ejeh F
Oncoscience; 2015; 2(2):99-101. PubMed ID: 25859552
[TBL] [Abstract][Full Text] [Related]
17. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
[TBL] [Abstract][Full Text] [Related]
18. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.
Hoang VT; Matossian MD; Ucar DA; Elliott S; La J; Wright MK; Burks HE; Perles A; Hossain F; King CT; Browning VE; Bursavich J; Fang F; Del Valle L; Bhatt AB; Cavanaugh JE; Flaherty PT; Anbalagan M; Rowan BG; Bratton MR; Nephew KP; Miele L; Collins-Burow BM; Martin EC; Burow ME
Front Oncol; 2020; 10():1164. PubMed ID: 32850332
[TBL] [Abstract][Full Text] [Related]
19. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
20. YAP promotes myogenic differentiation
Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
